Primary mediastinal large B cell lymphoma

Yating Yu1† | Xifeng Dong1† | Meifeng Tu2 | Huaquan Wang1

1Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China
2Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China

Correspondence
Huaquan Wang, Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
Email: wanghuaquan@tmu.edu.cn
Meifeng Tu, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.
Email: tmfsjj@hotmail.com

Funding information
Application Bases and Advanced Technology Research Program of Tianjin China, Grant/Award Numbers: 09JCJC11200, 14JCJC27200; Key Technology Research and Development Program of Tianjin China, Grant/Award Number: 18ZXDBSY00140; National Natural Science Foundation of China, Grant/Award Numbers: 81170472, 32100656

INTRODUCTION

Primary mediastinal large B cell lymphoma (PMBCL) is a rare subtype of aggressive B cell lymphoma. It constitutes 2%–3% of all cases of non-Hodgkin’s lymphoma (NHL).1 PMBCL was first described in the early 1980s, when it was previously classified as a diffuse large B cell lymphoma (DLBCL) subtype.2 Due to its the unique clinical, histological and molecular characteristics, PMBCL has been listed as a separate type in lymphoma classification by the World Health Organization since 2016.3

Epidemiology

The annual incidence of PMBCL is 0.4/million based on more than 400 patients diagnosed between 2000 and 2012, mostly adolescents and young adults (AYAs).1 It mainly occurs in patients in the age range of 30–39 years and has a predominance among females, especially among white people. Obesity, immune disorders, infection, genetics and occupational factors can lead to NHL, but no specific risk factors have been identified for PMBCL.4

HISTOLOGICAL FEATURES

Most cases of PMBCL are reported to originate in the anterior superior mediastinum of the thymus region, with bulky masses, 60%–70% of which are larger than 10 cm in diameter. The lungs, pleura and pericardium are often involved. The tumor cells are usually medium to large, with abundant cytoplasm, grayish white and round or oval nuclei. Fibrosis around tumor cells leads to diffuse proliferation, leading to separation and sclerosis.3 PMBCL

Abstract

Primary mediastinal large B cell lymphoma (PMBCL) is an aggressive large B cell lymphoma originating in the mediastinum, that mainly expresses B cell surface molecules, such as CD19, CD20, CD22, and CD79a. Clinically, they are characterized by rapidly increasing anterior mediastinal masses, which can cause compression of the surrounding tissues. The diagnosis of PMBCL mainly depends on the pathological features, imaging examination and clinical features. Currently, the most commonly used therapeutic regimens are R-CHOP and R-EPOCH. Radiotherapy is beneficial in some patients, but it can also lead to long-term toxicity. The research and development of novel therapies are ongoing, and some studies have achieved encouraging results, including those conducted on chimeric antigen receptor-modified T (CAR-T) cell therapy and anti-PD-1 drugs. However, randomized controlled trials with larger sample sizes are still needed. Positron emission tomography-computed tomography (PET-CT) is mainly used to assess the curative effect after treatment and to guide the subsequent treatment strategy.

KEYWORDS
diagnosis, drug therapy, immunotherapy, primary mediastinal large B-cell lymphoma
malignant cells originate from thymic B cells and express B cell antigens such as CD19, CD20, CD22 and CD79a, but do not express surface immunoglobulins. B cell transcription factors are often positive, including PAX5, OCT2, BCL6, PU1, IRF4 and BOB1. CD30 is weakly expressed and CD15 was negative. CD23, MAL, PDL1 and PDL2 are frequently expressed.

The most common chromosomal abnormalities are +9p, +12q and +Xq. The +9p results in abnormal expansion of JAK2 located on 9p24 and abnormal regulation of the JAK–STAT pathway, overexpression of PDL1 and PDL2, and downregulation of MHC-II and CIIA lead to the survival of PMBCL malignant cells in the thymic microenvironment. Abnormally activated JAK–STAT is involved in oncogene activation, tumor suppressor gene inactivation, abnormal cell proliferation, tumor growth and metastasis. PMBCL has a structurally activated NF-κB pathway. Nonsense and frameshift mutations in TNFAIP3 lead to NF-κB activation. Therefore, blocking NF-κB, JAK–STAT pathway and PD-1 antibody may be a potential therapeutic strategy.

CLINICAL MANIFESTATION

The characteristic clinical manifestation of PMBCL is a fast-growing mass in the anterior mediastinum, which leads to local compressed respiratory symptoms, including superior vena cava syndrome, pleural or pericardial effusion. Common symptoms include cough, dyspnea, hoarseness, dysphagia, airway or vascular damage, and B symptoms (fever, night sweats, and weight loss). Lactate dehydrogenase (LDH) is also elevated. The involvement of distant lymph nodes and bone marrow is rare. Eighty percent of cases are diagnosed as stage I–II.

IMAGING

The main imaging methods for PMBCL diagnosis are computed tomography (CT), magnetic resonance imaging (MRI) and PET/CT. CT is the first-line examination method that can detect primary lymph node enlargement and surrounding tissue. On CT, the mass usually shows low-density features, including varying degrees of bleeding, necrosis or cystic changes. Other imaging findings include unilateral diaphragm elevation, pleural effusion and pericardial effusion. PET/CT plays an important role in the evaluation of remission status (Figure 1).

PET/CT can distinguish fibrosis, necrosis and active tumor, and is used for staging, diagnosis, and early response assessment after immunochemotherapy. A study of 113 patients showed that the 5-year overall survival (OS) of PET/CT-negative and PET/CT-positive patients was 97% and 88%, respectively. In the RT era (R-CHOP-RT), 78% received RT treatment. In the era of PET (only patients with positive end-of-treatment [EOT] PET scan received RT), 28% received RT. Comparing the results of the RT and PET eras, the 5-year OS rates were 86% and 91%, respectively. EOT-PET was used to guide the application of consolidated RT, which reduced the usage by 64% without affecting the cure. PET/CT has a good negative predictive value, but its positive predictive value is limited. After treatment, mediastinal inflammatory tissue and tissue reactions may lead to a high false-positive rate. LDH levels and several PET/CT findings (tumor size, presence of necrosis, and degree of F-FDG uptake) are helpful in discriminating other diseases from PMBCL. The PET Deauville score can be used to determine which patients cannot receive consolidative radiotherapy. Deauville negative (1–3 points) patients were closely followed up with no intervention before disease progression. Deauville (4 points) patients may be due to a post-chemotherapy inflammatory response, leading to a high false-positive rate. The treatment of false-positive patients is also controversial. Some investigators suggest that consolidative radiotherapy should be combined, while others believe that they can be closely observed by PET/CT and biopsy. Deauville (5 points) patients will receive radiotherapy, second-line chemotherapy, checkpoint inhibitors, or high-dose chemotherapy and transplantation according to the judgment of the physician. In addition to the Deauville score, metabolic tumor volume, total lesion glycolysis (TLG), and area under the curve of cumulative SUV histogram (AUC-CSH) based on PET/CT technology might be sensitive indicators for predicting progression-free survival (PFS) and OS. TLG is the best predictor of individual prognosis, and elevated TLG can determine an increased risk of progression.
in patients. At 5 years, OS was 100% in patients with low TLG, 80% in patients with high TLG \(p = 0.0001\), and PFS was 99% and 64% \(p < 0.0001\), respectively. Moreover, baseline TLG combined with the Deauville score may show a better positive predictive value.

**DIAGNOSTIC CRITERIA AND STAGING**

The diagnosis and staging of PMBCL depends on pathological, imaging and clinical features. The prominent features of PMBCL are a rapidly enlarged anterior mediastinal mass, expression of B-cell surface molecules by immunohistochemistry, pale cytoplasm and polymorphonuclear cells under light microscopy, and fibrosis around the nucleus. Hardening occurred in half of the cases. Staging was performed according to the Ann Arbor clinical staging system.

**DIFFERENTIAL DIAGNOSIS**

PMBCL needs to be differentiated from DLBCL, mediastinal gray zone lymphoma (MGZL) and cHL (especially nodular sclerosis classical Hodgkin’s lymphoma). It is difficult to distinguish based on clinical manifestation alone, and the final diagnosis requires a combination of morphological, immunophenotypic and imaging indicators (Table 1). CD79a, BOB1 and cycline (cHL is 100%) are helpful in distinguishing cHL from PMBCL. MAL, CD200 and CD23 can be used to identify PMBCL and DLBCL. The gene expression profile (lymph3cx) can be used to identify difficult cases.

### Treatment

**First-line treatment**

At present, the National Comprehensive Cancer Network (NCCN) guidelines recommend the DA-EPOCH-R regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) with or without RT, and the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) combined with RT and R-CHOP can bridge the ICE regimen (ifosfamide, carboplatin, etoposide), and can be combined with rituximab or RT.

In the prerituximab era, M/VACOP-B (methotrexate/etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) was better than CHOP, and combined radiotherapy could also increase the efficacy. The efficacy of the rituximab combined regimen was significantly improved. The MInT study showed that after combination with rituximab, CR increased from 54% to 80%, 3-year event-free survival (EFS) increased from 52% to 78%, and 3-year OS increased from 78% to 89%. German research shows that PFS and OS in 10 years are 67% and 72%, respectively without combining with rituximab. After combining with rituximab, PFS and OS increased to 95% and 92%, respectively. Some studies have shown that the long-term OS and/orPFS of first-line R-EPOCH is better, but some studies have shown that R-CHOP-21 has the same curative effect as R-EPOCH, and the incidence of grade 3–4 adverse events is lower. The CR rate was higher in patients treated with DA-R-EPOCH than in those treated with R-CHOP (84% vs. 70%, \(p = 0.046\)). Consolidative mediastinal radiation was more common after R-CHOP than after DA-R-EPOCH (59% vs. 13%, \(p < 0.001\)).

| TABLE 1 | The identification of PMBCL, DLBCL, cHL and MGZL |
| --- | --- | --- | --- |
| **Primary mediastinal B cell lymphoma (PMBCL)** | **Diffuse large B cell lymphoma (DLBCL)** | **Classic Hodgkin’s lymphoma (cHL)** | **Mediastinal gray zone lymphoma (MGZL)** |
| **Origin** | Thymic medullary B cells | Lympy node germinal center, activated B cells | Lympy node germinal center | Thymic B cells |
| **Epidemiology** | | | | |
| Median age | 33 | 55 | 28 | 35 |
| Sex predominance | Female | Male | Varies by subtype | Male |
| **Clinical manifestation** | | | | |
| Mediastinal involvement | 100% | 20% | 80% | 80% |
| B symptoms | <20% | 50% | 40% | 40% |
| Distant metastasis | Rare | Common | Rare | Rare |
| Biopsy site | Biopsy of mediastinal mass | LN excisional or cutting-needle biopsy | Bone marrow core biopsy, excisional biopsy | Biopsy of mediastinal mass |
| **Treatment** | | | | |
| Treatment plan | R-CHOP + RT, DA-EPOCH-R (+RT) | R-CHOP, R-ACVBP | ABVD + RT, BEACOPP | R-CHOP, ABVD-R, DA-EPOCH-R |
| **Salvage therapy** | HDT/ASCT, PD-1 | HDT/ASCT | HDT/ASCT | HDT/ASCT |

Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; HDT/ASCT, high-dose therapy followed by autologous hematopoietic cell transplantation; R-ACVBP, rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; RT, radiotherapy.
However, patients treated with DA-R-EPOCH were more likely to experience treatment-related diseases, such as neutropenic fever and acute toxicities (Table 2).22

**Radiotherapy**

PMBCL is a radiosensitive disease, and consolidation mediastinal radiotherapy can improve its curative effect.5 However, PMBCL patients are young and have a long life expectancy, therefore, the long-term toxicity of radiotherapy should be considered. Radiotherapy may increase the risk of a second malignancy, especially breast cancer and cardiotoxicity.1 Based on the limited published data, it is strongly recommended that the R-CHOP regimen be combined with radiotherapy. However, for the DA-EPOCH-R regimen, EOT-PET is recommended to guide RT.9 It has been confirmed that the use of dose-intensive therapy without radiotherapy can also achieve a good curative effect.5 Moreover, some studies have shown that R-CHOP combined with RT and DA-EPOCH-R regimen without RT can achieve similar efficacy, but whether high-dose chemotherapy can replace RT remains to be discussed.33

**Treatment of relapsed/refractory PMBCL**

Disease recurrence usually occurs in the early stage, and recurrence-refractory patients account for 10%–30% of the total number of cases.34 High-dose therapy followed by autologous hematopoietic cell transplantation (HDT/ASCT) and immune checkpoint blockade therapy are effective treatments for relapsed or refractory PMBCL.35

The total effective rate of HDT/ASCT was 77.2% (complete remission, 63.6%). The median follow-up time was 53.5 months. The 4-year OS and PFS rates were 70% and 61%, respectively. The 4-year OS rates of patients with relapse and primary refractory diseases were 73% and 65%, respectively.34 The 2-year OS and PFS of allo SCT were 45% and 39%, respectively. Allo SCT treatment has high transplant-related mortality.36 Moreover, it may produce durable remission in a proportion of patients with treatment-sensitive disease before transplantation.37

The most promising target of immune checkpoint blockade for PMBCL is PD-1. The US Food and Drug Administration (FDA) has approved the use of pembrolizumab for patients with RR PMBCL. PD-1 blockade therapy enhances the immune response mainly by reactivating the existing anti-tumor T cells in situ, rather than activating de novo antitumor T cells, which is defined as a checkpoint blockade therapy (CBT)-responsive lymphoma (i.e., inflamed lymphomas), and its lymphoma environment is enriched in infiltrating immune cells.38 In addition to the overexpression of PD-L1 and PD-L2, there are two aspects which give immune checkpoint inhibitors a good therapeutic potential. Pembrolizumab is an anti-PD-1 immune checkpoint inhibitor that has been approved by the FDA for PMBCL patients with progression after two or more treatment regimens. It has a high response rate, persistent activity, and manageable safety.39–41 In the KEYNOTE-013 study, 21 patients with relapsed or refractory PMBCL were treated with pembrolizumab. The objective response rate (ORR) was 48%, including seven CR and three PR. In 81% of patients, the lesions shrank. A phase 2 trial showed that in 53 patients, the ORR was 45%, including 7 CR (13%) and 17 PR (32%).41 PD-1 monoclonal antibodies combined with chemotherapy can further improve efficiency. Camrelizumab combined with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) was used to treat 27 cases of relapsed or refractory PMBCL. The data showed that the ORR was 74%, the CR was 56%, the median response time was

### Table 2 Comparison of different treatment schemes for PMBCL

| Treatment plan | Number of patients | CR rate | PFS | OS | Reference |
|----------------|--------------------|---------|-----|----|-----------|
| Before rituximab |                   |         |     |    |           |
| CHOP (6)        | 21                 | 0       | 90% (3 years) |    | 23        |
| MACOP-B (15)    |                   | 87%     |      |    |           |
| CHOP (14)       | 29                 | 36%     | 72% (3 years) |    | 24        |
| MACOP-B (15)    |                   | 73%     |      |    |           |
| MACOP-B + RT    | 92                 | 87%     | 84% (5 years) | 88% (5 years) | 25 |
| After rituximab administration | |         |     |    |           |
| M/VACOP-B (47)  | 153                | 77%     | 69% (5 years) | 87% (5 years) | 26 |
| R-CHOP (19)     |                   |         |      |    |           |
| CHOP (67)       |                   |         |      |    |           |
| CHOP-like (43)  | 45                 | 80%     | 88% (5 years) | 80% (5 years) | 27 |
| R-CHOP-like (44)| 87                 | 32.6% 52.3% | 52% (3 years) | 78.2% (3 years) | 28 |
| CHOP (76)       | 121                | Not analyzed | 81% (5 years) | 89% (5 years) | 29 |
| R-CHOP (45)     | 80                 | 13%     | 95% (10 years) | 92% (10 years) | 30 |
| CHOP (35)       |                   | 37%     | 67% (10 years) | 72% (10 years) | 31 |
| R-CHOP          | 63                 | 71%     | 68% (5 years) | 79% (5 years) | 32 |
| R-MACOP-B       | 74                 | 82.4%   | 87.6% (10 years) | 82% (10 years) | 33 |
| R-CHOP (56)     | 132                | 69.6%   | 76% (2 years) | 89% (2 years) | 22 |
| DA-EPOCH-R (76) |                   | 84.2%   | 85% (2 years) | 91% (2 years) | 24 |
1.7 months, and 78% showed tumor shrinkage at the first evaluation.42 The ORR of the PD-1 antibody nivolumab combined with brentuximab vedotin for the treatment of relapsed or refractory PMBCL was higher, up to 73%, but the number of adverse events were more than that of penbrolizumab alone (83%). A total of 16 patients (53%) had grade 3 to 4 treatment-related adverse events; the most common were neutropenia (n = 9), thrombocytopenia (n = 3), and peripheral neuropathy (n = 3).43 The combination of platinum-based chemotherapy and PD-1/PD-L1 inhibitors has also shown therapeutic potential.44

**Novel therapies**

The potential targets of PMBCL therapy include specific cell surface markers, cell signal transduction pathways, programmed death ligands, etc. At present, several new drugs for PMBCL therapy are undergoing clinical trials, some of which have achieved encouraging results.

**Chimeric antigen receptor T (CART) cell therapy**

Anti-CD19 CAR-T cell therapy shows good therapeutic prospects. CD19 is a common target antigen in hematological malignancies, and is commonly found on B cells.7 ZUMA-1 included 101 patients with RR-DLBCL, PMBCL (n = 8) and transformed FL. Among all patients in 1 year, ORR was 82%, CR was 54%, with a median follow-up of 15.4 months, 42% of the patients continued to have a response, with 40% continuing to have a complete response, and 18 month survival was 52%.45 The longest follow-up time of anti-CD19 CAR-T cell therapy for PMBCL/DLBCL was 97 months. The peak level of CAR-T cells in peripheral blood is related to the response, but the level of CAR-T cells 28–56 days after infusion is not related to the response, and the degree of persistence of CAR-T cells required for remission of persistent lymphoma is unclear.46 CAR-T cell therapy is associated with cytokine release syndrome, and nerve events and treatment-related death may occur,35 but the incidence of severe cytokine release syndrome and nervous system events is low. In the transcend NHL 001 study, 344 cases of RR-DLBCL (including 15 cases of PMBCL) were treated with anti-CD19 CAR-T. The effective and CR rates were 73% and 53%, respectively. Grade 3 and above cytokine syndrome and neurological reactions were 2% and 10%, respectively.47

**Brentuximab vedotin**

The anti-CD30 antibody drug conjugate brentuximab vedotin (BV) has been approved for the treatment of relapsed or refractory HD and anaplastic large cell lymphoma (ALCL). PMBCL also expresses CD30, but its expression level is low. In a phase II trial, the effective rate was 17% in six cases of PMBCL and three cases of SD. The reaction was not related to the quantitative expression of CD30 on tumor cells.48 In another study, 15 cases of relapsed PMBCL were treated with BV, with a total effective rate of 13.3% (2/15), two cases of PR, one case of SD and 12 cases of PD.49 Although BV single drug therapy results are poor, when combined with immunotherapy, good results have been reported. A total of 29 cases of PMBCL were treated with BV combined with R-CHP. The effective rates were 100%, 86% and 14% PR with 2-year PFS of 85%, and 2-year OS of 100%.50

**Bispecific T cell engager (BiTE) antibody**

BiTE can simultaneously bind two different antigens. Blinatumomab is a CD19/CD3 BiTE double antibody that is used to treat Philadelphia chromosome-negative acute B-lymphoblastic leukemia. Blinatumomab connects CD3 + polyclonal T cells to CD19 + B cells, induces T cell activation, and T cell-mediated B-cell lysis. Single drug blinatumomab has been reported to show antilymphoma activity in relapsed or refractory NHL, and PMBCL data needs to be studied further.51

**JAK inhibitors**

Abnormal activation of the JAK–STAT pathway in PMBCL malignant cells leads to cell proliferation, survival, angiogenesis and transcription of immune target genes. The role of JAK inhibitors in PMBCL has also been studied, and ruxolitinib is ineffective (Figure 2).53

**PROGNOSIS**

The 5-year survival rate of patients with PMBCL is approximately about 85%. The International prognostic index (IPI), age, LDH, stage, Ki-67 proliferation index and SUVmax of PET-CT are significantly correlated with survival rate.33 MUM1 expression and higher peripheral blood lymphocyte/monocyte ratio are significantly correlated with a better survival rate.35

In conclusion, PMBCL is a rare subtype of aggressive B-cell lymphoma, which is more common in adolescents and young adults, mainly women. Treatment should consider maximum efficacy and minimize long-term toxicity. R-CHOP + RT and DA-EPOCH-R ± RT are effective first-line choices for PMBCL. Autologous or allogeneic SCT.
after high-dose chemotherapy is an effective treatment strategy for relapsed or refractory PMBCL. Following immunochemotherapy, FDG-PET is used to evaluate the therapeutic effect and decide whether radiotherapy should be used. Some new therapies have shown good prospects, and clinical trials are currently in progress.

ACKNOWLEDGMENTS
This project was partly supported by The National Natural Science Foundation of China (no. 81170472, 32100656), Key Technology Research and Development Program of Tianjin China (18ZXDBSY00140), Application Bases and Advanced Technology Research Program of Tianjin China (no. 14JCYBJC27200, 09JCYBJC11200).

CONFLICT OF INTEREST
All authors declare no conflict of interest.

ORCID
Yuting Yu https://orcid.org/0000-0003-3314-8733
Xifeng Dong https://orcid.org/0000-0003-1278-129X
Huaquan Wang https://orcid.org/0000-0003-2402-2717

REFERENCES
1. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–27.
2. Barth TFE, Leithäuser F, Joos S, Bentz M, Möller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3(4):229–34.
3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Sobin LH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
4. Pfaff D, Smith DA, Beck R, Gilani KA, Gupta A, Caimi P, et al. Primary mediastinal large B-cell lymphoma: a review for radiologists. Am J Roentgenol. 2019;213(5):W194–210.
5. Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood. 2018;132(8):782–90.
6. Twa DDW, Chan FC, Ben-Neriah S, Woolcock BW, Mottak A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–5.
7. Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185(1):25–41.
8. Szydłowski M, Dębek S, Prochorec-Sobieszek M, Szołkowska M, Tomirotti AM, Juszczyński P, et al. PI3K kinases promote survival and immune escape in primary mediastinal large B-cell lymphoma through modulation of JAK-STAT and NF-kB activity. Am J Pathol. 2021;193(3):567–74.
9. Hayden AR, Tonselli P, Lee DG, Villa D, Gerrie AS, Scott DW, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood. 2020;136(24):2803–11.
10. Alkhawtani RHM, Noordzij W, Glaudemans AWJM, van Rijn RS, van der Galiën HT, Balink H, et al. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma. Nucl Med Commun. 2018;39(6):572–8.
11. Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, et al. Primary mediastinal B cell lymphoma in the positron-emission tomography era executive summary of the American Radium Society appropriate use criteria. Int J Radiat Oncol Biol Phys. 2021;111(1):36–44.
12. Meignan M. Quantitative FDG-PET: a new biomarker in PMBCL. Blood. 2015;126(8):924–6.
13. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, et al. Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018;2(11):1334–43.
14. Ceriani L, Martelli M, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, et al. Utility of baseline 18F-FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950–6.
15. Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol. 2017;178(4):588–91.
16. Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised. 4th ed. Lyon, France: IARC Press; 2017. p. 314–6.
17. Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL CD23 and other markers. Mod Pathol. 2012;25(12):1637–43.
18. Mottok A, Wight G, Rosenwald A, Ott G, Ramsower C, Campo E, et al. PIM kinases promote survival and immune escape in primary mediastinal large B-cell lymphoma. Am J Pathol. 2019;201(3):1190–20.
19. Lim MS. PMBCL: a molecular diagnosis? Blood. 2018;132(22):2319–20.
20. Wang Z, Cook JR. PDCD1L1-G2 (PD-1-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma. Br J Haematol. 2018;181(4):564–6.
21. Malenda A, Kolkowska-Leśniak A, Pula B, Długosz-Danecka M, Cibulska M, Kośinka A, et al. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol. 2020;104(1):39–66.
22. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-Centre analysis. Br J Haematol. 2018;180(4):534–44.
23. Todeschini G, Ambrosetti A, Meneghini V, Pizzolo G, Menestrina F, Chilosi M, et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol. 1990;8(5):804–8.
24. Lazzarino M, Orlandi E, Pauli M, Boveri E, Morra E, Brusamolino E, et al. Primary mediastinal B-cell lymphoma with sclerosis: an
aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol. 1993;11(12):2306–13.

25. De Sanctis V, Finolezzi E, Osti MF, Grapulin L, Alfò M, Pescarmona E, et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys. 2008;72(4):1154–60.

26. Savage KJ, Al-Rajhi N, Voss N, Paltci G, Klasa R, Gasconye RD, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):123–30.

27. Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9(5):381–3.

28. Rieger M, Österborg A, Pettengell R, White D, Gill D, Walewski J, et al. Allogeneic stem cell transplantation provides durable remission for primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267

29. Zinzani PL, Broccoli A, Casadei B, Stefoni V, Pellegrini C, Gandolfi L, et al. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. BMC Cancer. 2017;17(1):359.

30. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55(3):338–43.

31. Lisenko K, Dingeldein G, Cremer M, Kriegsmann M, Ho AD, Rieger M, et al. Addition of rituximab to CHOP-like chemotherapy for primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol. 2015;33(4):145–50.

32. Chen EHL, Koh LP, Lee J, de Mel S, Jeyasekharan A, Liu X, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal large B-cell lymphoma: evidence from 74 patients. Haematol Oncol. 2015;33(4):145–50.

33. Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, et al. prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020;10(5):49.

34. Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, et al. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. Br J Haematol. 2019;186(6):e219–23.

35. Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, et al. Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma. Biol Blood Marrow Transplant. 2019;25(12):2383–7.

36. Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523–33.

37. Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267–70.

38. Tomassetti S, Chen R, Dandapani S. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol. 2019;10:204602701984159.

39. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291–9.

40. Mei Q, Zhang W, Liu Y, Yang Q, Rasko JEJ, Nie J, et al. Camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin in relapsed/refractory primary mediastinal B-cell lymphoma: a single-arm, open-label, phase II trial. Clin Cancer Res. 2020;26(17):4521–30.

41. Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with Brentuximab Vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol. 2019;37(33):3081–9.

42. Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, et al. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021;18(2):187–203.

43. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

44. Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38(32):3805–15.

45. Abramson JS, Palomba ML, Gordon LJ, Lunning MA, Wang M, Arnason J, et al. Lisoctabagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

46. Jacobsen ED, Sharmar JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.

47. Zinzani PL, Pellegrini C, Chiappella A, di Rocco A, Salvi F, Cabras MG, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328–30.

48. Svoboda J, Bair SM, Landsburg DJ, Nasta SD, Nägele SJ, Barta SK, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2020;106(6):1705–13.

49. Goebeler M-E, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a Phase I Study. J Clin Oncol. 2016;34(10):1104–11.

50. Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma: final results from a Phase I Study. J Clin Oncol. 2016;34(10):1104–11.

51. Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma: final results from a Phase I Study. J Clin Oncol. 2016;34(10):1104–11.

52. Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma: final results from a Phase I Study. J Clin Oncol. 2016;34(10):1104–11.